Trastuzuma
Phase 2Small molecule
Trastuzuma is one of 34 small molecule programs targeting Breast Cancer. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Tykerb
GSKPreclinical
DATROWAY
Daiichi SankyoPreclinical
MS Contin
Merck & Co.Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Trastuzuma
FFudan University
Phase 2
Feraheme
AAzurity Pharmaceuticals
Preclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trastuzuma. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFudan University